Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy - 27/04/24
Abstract |
Chemoimmunotherapy has emerged as a promising strategy for improving the efficacy of cancer treatment. Herein, we present PD-1 receptor-presenting membrane-coated paclitaxel dimers nanoparticles (PD-1@PTX2 NPs) for enhanced treatment efficacy. PD-1 cell membrane-cloaked PTX dimer exhibited effective cellular uptake and increased cytotoxicity against cancer cells. PD-1@PTX2 NPs could selectively bind with PD-L1 ligands expressed on breast cancer cells. Our nanoparticles exhibit a remarkable tumor growth inhibition rate of 71.3% in mice bearing 4T1 xenografts and significantly prolong survival in mouse models of breast cancer. Additionally, our nanoparticles promoted a significant 3.2-fold increase in CD8+ T cell infiltration and 73.7% regulatory T cell (Treg) depletion within tumors, boosting a robust antitumor immune response. These findings underscore the potential of utilizing immune checkpoint receptor-presented PTX nanoparticles to enhance the efficacy of chemoimmunotherapy, providing an alternative approach for improving cancer treatment.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Paclitaxel dimer nanoparticles decorated with PD-1 cell membranes were developed for treating breast cancer. |
• | PD-1@PTX2 NPs significantly suppressed tumor growth and prolonged survival in mice bearing 4T1 xenograft. |
• | PD-1@PTX2 NPs elicited a robust antitumor immune response for enhanced immunotherapy. |
Keywords : PD-1, Paclitaxel dimer, Cell membrane, Drug delivery, Chemoimmunotherapy
Plan
Vol 174
Article 116482- mai 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?